Researchers track pregnancy outcomes for women on common eczema and asthma drug
NCT ID NCT04173442
Summary
This study aimed to understand the safety of using the medication dupilumab during pregnancy. Researchers followed 581 pregnant women in North America, comparing those who took the drug for eczema or asthma to those who did not. The main goal was to check for any effects on the baby's development and health during the first year of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Research Site
La Jolla, California, 92093-0934, United States
Conditions
Explore the condition pages connected to this study.